Pembrolizumab (new indication: endometrial carcinoma with MSI-H or dMMR tumors, pretreated patients)



  • Active Sustance: Pembrolizumab
  • Name: Keytruda®
  • Therapeutic area: Endometrial carcinoma
  • Pharmaceutical company: MSD Sharp & Dohme GmbH


Time table:

  • Start: 01.08.2022
  • Publication of assessment: 01.11.2022
  • End of public hearing: 22.11.2022
  • Final decision by G-BA: middle of January 2023


Comparative therapy:

  1. Therapy at the physician's discretion, appropriate therapies include:
    - endocrine therapy (medroxyprogesterone acetate, megestrol acetate) OR
    - systemic chemotherapy, which may include platinum-based re-therapy (cisplatin (monotherapy or in combination with doxorubicin), doxorubicin (monotherapy or in combination with cisplatin), carboplatin in combination with paclitaxel, paclitaxel (monotherapy) OR
    - Best Supportive Care